XM tillhandahåller inte tjänster till personer bosatta i USA.

B
B

BayerAG

Nyheter

Reuters - 13 timmar sedan

DC reaches $57 million deal with Exelon utility over PCB pollution

DC reaches $57 million deal with Exelon utility over PCB pollution By Clark Mindock Oct 3 (Reuters) - The attorney general of Washington, D.C., on Tuesday announced the city had reached settlements worth at least $57 million with an Exelon-owned EXC.O electric utility over claims the company polluted the Anacostia River with toxic chemicals called polychlorinated biphenyls, or PCBs.
B
E
Reuters - 6 dagar sedan

Merck's blood vessel disorder therapy receives US FDA's priority review

UPDATE 2-Merck's blood vessel disorder therapy receives US FDA's priority review Adds background throughout Sept 28 (Reuters) - Merck MRK.N said on Thursday the U.S. health regulator will review its experimental therapy to treat a type of progressive blood vessel disorder on a priority basis. The drugmaker had gained rights to the therapy, sotatercept, through its $11.5 billion acquisition of Acceleron Pharma in 2021. The U.S.
B
Reuters - 6 dagar sedan

Bayer To Present New Aflibercept 8 Mg 60-Week And 96-Week Data

BRIEF-Bayer To Present New Aflibercept 8 Mg 60-Week And 96-Week Data Sept 28 (Reuters) - Bayer AG BAYGn.DE : BAYER TO PRESENT NEW AFLIBERCEPT 8 MG 60-WEEK AND 96-WEEK DATA FOR PATIENTS WITH NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA A KEY SECONDARY ENDPOINT FROM 60-WEEK DATA FROM PIVOTAL PULSAR AND PHOTON AFLIBERC
B
Reuters - 1 vecka sedan

Pharma lobby says EU ban on 'forever chemicals' would halt drug production

Pharma lobby says EU ban on 'forever chemicals' would halt drug production By Ludwig Burger FRANKFURT, Sept 27 (Reuters) - European drugmakers warned that a proposed complete ban on substances known as PFAS or " forever chemicals " would render medicine production in the region impossible, part of a high-stakes wrangle between manufacturers and environmental regulators.
B
N
P
Reuters - 1 vecka sedan

Close Brothers Group, Derwent London, Klepierre

EUROPE RESEARCH ROUNDUP-Close Brothers Group, Derwent London, Klepierre Sept 25 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Close Brothers Group, Derwent London and Klepierre, on Monday. HIGHLIGHTS * Adyen NV ADYEN.AS : Stifel cuts target price to EUR 720 from EUR 1,900 * Close Brothers Group Plc CBRO.L : JP Morgan raises to neutral from underweight * Derwent London Plc DLN.L : RBC raises to sector perform from underperform * K
A
A
B
B
B
C
C
D
D
G
H
I
K
S
S
B
J
Reuters - 2 veckor sedan

Motor racing-AlphaTauri confirm Tsunoda and Ricciardo for 2024

UPDATE 2-Motor racing-AlphaTauri confirm Tsunoda and Ricciardo for 2024 Tsunoda and Ricciardo to be race line-up Lawson to serve as reserve for both Red Bull teams Recasts with fresh quotes, adds Lawson's role SUZUKA, Japan, Sept 23 (Reuters) - AlphaTauri confirmed Daniel Ricciardo and Yuki Tsunoda as their 2024 Formula One lineup on Saturday and said current stand-in Liam Lawson would be reserve driver for both of Red Bull's teams.
B
Reuters - 2 veckor sedan

Big Pharma bets on AI to speed up clinical trials

INSIGHT-Big Pharma bets on AI to speed up clinical trials Repeats for additional subscribers By Natalie Grover and Martin Coulter LONDON, Sept 22 (Reuters) - Major drugmakers are using artificial intelligence to find patients for clinical trials quickly, or to reduce the number of people needed to test medicines, both accelerating drug development and potentially saving millions of dollars.
A
B
N
R
Reuters - 2 veckor sedan

Hologic And Bayer Announce International Partnership To Deliver Comprehensive Contrast-Enhanced Mammography Package To Breast Imaging Facilities

BRIEF-Hologic And Bayer Announce International Partnership To Deliver Comprehensive Contrast-Enhanced Mammography Package To Breast Imaging Facilities Sept 21 (Reuters) - Hologic Inc HOLX.O : HOLOGIC AND BAYER ANNOUNCE INTERNATIONAL PARTNERSHIP TO DELIVER COMPREHENSIVE CONTRAST-ENHANCED MAMMOGRAPHY PACKAGE TO BREAST IMAGING FACILITIES HOLOGIC: CO,
B
H
Reuters - 2 veckor sedan

Bayer To Collaborate With Hologic In Breast Cancer Imaging

BRIEF-Bayer To Collaborate With Hologic In Breast Cancer Imaging Sept 21 (Reuters) - Bayer AG BAYGn.DE : TO COLLABORATE WITH HOLOGIC IN BREAST CANCER IMAGING Further company coverage: [BAYGn.DE] (Gdansk Newsroom)
B
Reuters - 2 veckor sedan

Bayer Expands Its Fruits And Vegetables Business To Strawberries

BRIEF-Bayer Expands Its Fruits And Vegetables Business To Strawberries Sept 21 (Reuters) - Bayer AG BAYGn.DE : EXPANDS ITS FRUITS AND VEGETABLES BUSINESS TO STRAWBERRIES AGREEMENT WITH UK-BASED NIAB TO ACQUIRE THEIR STRAWBERRY PIPELINE AND COMMERCIAL PORTFOLIO FOCUS ON LARGE-SCALE PROFESSIONAL STRAWBERRY GROWERS TO MEET GROWING CONSUMER AND RETAIL
B
Reuters - 2 veckor sedan

Bayer Issues 1.75 Billion Euro Hybrid Bond

BRIEF-Bayer Issues 1.75 Billion Euro Hybrid Bond Sept 20 (Reuters) - Bayer AG BAYGn.DE : ISSUES 1.75 BILLION EURO HYBRID BOND NEW ISSUE OF TWO TRANCHES WITH A NON-CALL PERIOD OF 5.25 AND 8.25 YEARS, RESPECTIVELY, COMBINED WITH A TENDER OFFER FOR TWO OF BAYER’S EXISTING HYBRID BONDS EACH TRANCHE HAS A FINAL MATURITY OF 60 YEARS FIRST TRANCHE IN AM
B
Reuters - 2 veckor sedan

EU executive proposes 10-year glyphosate approval extension

UPDATE 1-EU executive proposes 10-year glyphosate approval extension Adds more on renewal process, Bayer comment in paragraph 7, campaign group in paragraph 8 By Philip Blenkinsop BRUSSELS, Sept 20 (Reuters) - The European Commission proposed on Wednesday extending EU approval for use of glyphosate, the active ingredient in Bayer AG's BAYGn.DE Roundup weed killer, by 10 years.
B
Reuters - 2 veckor sedan

European Commission proposes 10-year approval extension for glyphosate

European Commission proposes 10-year approval extension for glyphosate BRUSSELS, Sept 20 (Reuters) - The European Commission proposed on Wednesday extending approval for glyphosate, the active ingredient in Bayer AG's BAYGn.DE Roundup weed killer, by 10 years. Glyphosate has been a focus of controversy since the World Health Organization's cancer agency concluded in 2015 that it was probably carcinogenic to humans.
B
Reuters - 2 veckor sedan

Amplifon, Clariant, Hugo Boss

EUROPE RESEARCH ROUNDUP-Amplifon, Clariant, Hugo Boss Sept 20 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Amplifon, Clariant and Hugo Boss, on Wednesday. HIGHLIGHTS * Amplifon AMPF.MI : HSBC raises to buy from hold * Clariant AG CLN.S : Jefferies raises to buy from hold * Hugo Boss AG BOSSn.DE : Jefferies raises to buy from hold * Kering PRTP.PA : Jefferies cuts to hold from buy * LVMH LVMH.PA : Jefferies cuts to hold from buy
A
B
B
C
C
D
E
E
H
H
K
K
K
L
M
O
P
P
R
R
S
S
S
S
A
A
F
P
P
S
U
Reuters - 3 veckor sedan

FTC competition head discloses $3.3 mln Covington pay, major clients

FTC competition head discloses $3.3 mln Covington pay, major clients By David Thomas Sept 15 (Reuters) - U.S. Federal Trade Commission antitrust leader Henry Liu earned more than $3.3 million from the beginning of last year through mid-August as a former partner at law firm Covington & Burling, where his clients included Apple, Eli Lilly, JPMorgan Chase and Visa, a newly released ethics filing shows.
A
A
B
J
V
Reuters - 3 veckor sedan

Bayer's new CEO plans to cut management jobs in prelude to overhaul

EXCLUSIVE-Bayer's new CEO plans to cut management jobs in prelude to overhaul Adds shares in paragraph 2, investor and trader comments in paragraphs 7-10 By Ludwig Burger and Patricia Weiss FRANKFURT, Sept 15 (Reuters) - Bayer's BAYGn.DE new CEO plans to cut management jobs to speed up decision-making as a first step to overhaul the embattled German industrial group, which is facing investor pressure to break up, three people familiar with the matter said.
B
R
G
Reuters - 3 veckor sedan

Bayer's new CEO plans to cut management jobs in prelude to overhaul

EXCLUSIVE-Bayer's new CEO plans to cut management jobs in prelude to overhaul Adds shares in paragraph 2, investor and trader comments in paragraphs 7-10 By Ludwig Burger and Patricia Weiss FRANKFURT, Sept 15 (Reuters) - Bayer's BAYGn.DE new CEO plans to cut management jobs to speed up decision-making as a first step to overhaul the embattled German industrial group, which is facing investor pressure to break up, three people familiar with the matter said.
B
R
G
Reuters - 3 veckor sedan

European shares set to end week higher after ECB signals end to rate hikes

CORRECTED-UPDATE 1-European shares set to end week higher after ECB signals end to rate hikes Corrects paragraph 8 to say Bank of England, not "Bank of America" ECB's Villeroy: loose budgets could fuel more inflation H&M's quarterly sales lag expectations, shares fall Luxury stocks rally on encouraging Chinese macro data STOXX 600 rises 0.9%, up 2.1% so far this week By Bansari Mayur Kamdar Sept 15 (Reuters) - European shares extended their rally on Friday, on track to end the week higher, follo
B
K
L
H
E
F
U
G
Reuters - 3 veckor sedan

Bayer's new CEO plans to cut management jobs in prelude to overhaul

RPT-EXCLUSIVE-Bayer's new CEO plans to cut management jobs in prelude to overhaul Repeats with no changes to text By Ludwig Burger and Patricia Weiss FRANKFURT, Sept 14 (Reuters) - Bayer's BAYGn.DE new CEO plans to cut management jobs to speed up decision-making as a first step to overhaul the embattled German industrial group, which is facing investor pressure to break up, three people familiar with the matter said.
B
R
Reuters - 3 veckor sedan

Bayer's new CEO plans to cut management jobs in prelude to overhaul

RPT-EXCLUSIVE-Bayer's new CEO plans to cut management jobs in prelude to overhaul Repeats with no changes to text By Ludwig Burger and Patricia Weiss FRANKFURT, Sept 14 (Reuters) - Bayer's BAYGn.DE new CEO plans to cut management jobs to speed up decision-making as a first step to overhaul the embattled German industrial group, which is facing investor pressure to break up, three people familiar with the matter said.
B
R

Villkor

Populära tillgångar

Ansvarsfriskrivning: XM Group-enheter tillhandahåller sin tjänst enbart för exekvering och tillgången till vår onlinehandelsplattform, som innebär att en person kan se och/eller använda tillgängligt innehåll på eller via webbplatsen, påverkar eller utökar inte detta, vilket inte heller varit avsikten. Denna tillgång och användning omfattas alltid av i) villkor, ii) riskvarningar och iii) fullständig ansvarsfriskrivning. Detta innehåll tillhandahålls därför uteslutande som allmän information. Var framför allt medveten om att innehållet på vår onlinehandelsplattform varken utgör en uppmaning eller ett erbjudande om att ingå några transaktioner på de finansiella marknaderna. Handel på alla finansiella marknader involverar en betydande risk för ditt kapital.

Allt material som publiceras på denna sida är enbart avsett för utbildnings- eller informationssyften och innehåller inte – och ska inte heller anses innehålla – rådgivning och rekommendationer om finansiella frågor, investeringsskatt eller handel, dokumentation av våra handelskurser eller ett erbjudande om, eller en uppmaning till, en transaktion i finansiella instrument eller oönskade finansiella erbjudanden som är riktade till dig.

Tredjepartsinnehåll, liksom innehåll framtaget av XM såsom synpunkter, nyheter, forskningsrön, analyser, kurser, andra uppgifter eller länkar till tredjepartssajter som återfinns på denna webbplats, tillhandahålls i befintligt skick, som allmän marknadskommentar, och utgör ingen investeringsrådgivning. I den mån som något innehåll tolkas som investeringsforskning måste det noteras och accepteras att innehållet varken har varit avsett som oberoende investeringsforskning eller har utarbetats i enlighet med de rättsliga kraven för att främja ett sådant syfte, och därför är att betrakta som marknadskommunikation enligt tillämpliga lagar och föreskrifter. Se till så att du har läst och förstått vårt meddelande om icke-oberoende investeringsforskning och riskvarning om ovannämnda information, som finns här.

Vi använder cookies för att ge dig den bästa upplevelsen på vår webbplats. Läs mer eller ändra dina cookie-inställningar.

Riskvarning: Ditt kapital riskeras. Hävstångsprodukter passar kanske inte alla. Se vår riskinformation.